182 related articles for article (PubMed ID: 16439521)
21. Cellular and humoral immune responses to a canarypox vaccine containing human immunodeficiency virus type 1 Env, Gag, and Pro in combination with rgp120.
AIDS Vaccine Evaluation Group 022 Protocol Team
J Infect Dis; 2001 Feb; 183(4):563-70. PubMed ID: 11170981
[TBL] [Abstract][Full Text] [Related]
22. Generation and immunogenicity of novel HIV/AIDS vaccine candidates targeting HIV-1 Env/Gag-Pol-Nef antigens of clade C.
Gómez CE; Nájera JL; Jiménez V; Bieler K; Wild J; Kostic L; Heidari S; Chen M; Frachette MJ; Pantaleo G; Wolf H; Liljeström P; Wagner R; Esteban M
Vaccine; 2007 Mar; 25(11):1969-92. PubMed ID: 17224219
[TBL] [Abstract][Full Text] [Related]
23. Robust HIV-specific immune responses were induced by DNA vaccine prime followed by attenuated recombinant vaccinia virus (LC16m8 strain) boost.
Shinoda K; Xin KQ; Kojima Y; Saha S; Okuda K; Okuda K
Clin Immunol; 2006 Apr; 119(1):32-7. PubMed ID: 16458074
[TBL] [Abstract][Full Text] [Related]
24. The adjuvancy of OX40 ligand (CD252) on an HIV-1 canarypox vaccine.
Liu J; Ngai N; Stone GW; Yue FY; Ostrowski MA
Vaccine; 2009 Aug; 27(37):5077-84. PubMed ID: 19573639
[TBL] [Abstract][Full Text] [Related]
25. Development of BCG as a live recombinant vector system: potential use as an HIV vaccine.
Fuerst TR; Stover CK; de la Cruz VF
Biotechnol Ther; 1991; 2(1-2):159-78. PubMed ID: 1845119
[TBL] [Abstract][Full Text] [Related]
26. Pseudovirion particle production by live poxvirus human immunodeficiency virus vaccine vector enhances humoral and cellular immune responses.
Chen X; Rock MT; Hammonds J; Tartaglia J; Shintani A; Currier J; Slike B; Crowe JE; Marovich M; Spearman P
J Virol; 2005 May; 79(9):5537-47. PubMed ID: 15827168
[TBL] [Abstract][Full Text] [Related]
27. A Tat subunit vaccine confers protective immunity against the immune-modulating activity of the human immunodeficiency virus type-1 Tat protein in mice.
Agwale SM; Shata MT; Reitz MS; Kalyanaraman VS; Gallo RC; Popovic M; Hone DM
Proc Natl Acad Sci U S A; 2002 Jul; 99(15):10037-41. PubMed ID: 12096189
[TBL] [Abstract][Full Text] [Related]
28. Cytotoxic T lymphocyte response in mice induced by a recombinant BCG vaccination which produces an extracellular alpha antigen that fused with the human immunodeficiency virus type 1 envelope immunodominant domain in the V3 loop.
Kameoka M; Nishino Y; Matsuo K; Ohara N; Kimura T; Yamazaki A; Yamada T; Ikuta K
Vaccine; 1994 Feb; 12(2):153-8. PubMed ID: 8147098
[TBL] [Abstract][Full Text] [Related]
29. Immunogenicity of recombinant Modified Vaccinia Ankara Viruses (rMVA) expressing HIV-1 Indian subtype C gag-protease and env-gp120 genes in mice.
Kumar S; Seth P
Viral Immunol; 2004; 17(4):574-9. PubMed ID: 15671754
[TBL] [Abstract][Full Text] [Related]
30. Novel CD8+ T cell-based vaccine stimulates Gp120-specific CTL responses leading to therapeutic and long-term immunity in transgenic HLA-A2 mice.
Nanjundappa RH; Wang R; Xie Y; Umeshappa CS; Xiang J
Vaccine; 2012 May; 30(24):3519-25. PubMed ID: 22484292
[TBL] [Abstract][Full Text] [Related]
31. Human immunodeficiency virus type 1 envelope-specific cytotoxic T lymphocytes response dynamics after prime-boost vaccine regimens with human immunodeficiency virus type 1 canarypox and pseudovirions.
Arp J; Rovinski B; Sambhara S; Tartaglia J; Dekaban G
Viral Immunol; 1999; 12(4):281-96. PubMed ID: 10630788
[TBL] [Abstract][Full Text] [Related]
32. Development and analysis of recombinant BCG vector systems.
Fuerst TR; de la Cruz VF; Bansal GP; Stover CK
AIDS Res Hum Retroviruses; 1992 Aug; 8(8):1451-5. PubMed ID: 1466980
[No Abstract] [Full Text] [Related]
33. Enhanced priming of adaptive immunity by Mycobacterium smegmatis mutants with high-level protein secretion.
Taylor N; Bahunde F; Thompson A; Yu JS; Jacobs WR; Letvin NL; Haynes BF; Lee S
Clin Vaccine Immunol; 2012 Sep; 19(9):1416-25. PubMed ID: 22787192
[TBL] [Abstract][Full Text] [Related]
34. A prime-boost immunisation regimen using recombinant BCG and Pr55(gag) virus-like particle vaccines based on HIV type 1 subtype C successfully elicits Gag-specific responses in baboons.
Chege GK; Thomas R; Shephard EG; Meyers A; Bourn W; Williamson C; Maclean J; Gray CM; Rybicki EP; Williamson AL
Vaccine; 2009 Jul; 27(35):4857-66. PubMed ID: 19520196
[TBL] [Abstract][Full Text] [Related]
35. Narrowed TCR diversity for immunised mice challenged with recombinant influenza A-HIV Env(311-320) virus.
Cukalac T; Moffat JM; Venturi V; Davenport MP; Doherty PC; Turner SJ; Stambas J
Vaccine; 2009 Nov; 27(48):6755-61. PubMed ID: 19744584
[TBL] [Abstract][Full Text] [Related]
36. Independent but not synergistic enhancement to the immunogenicity of DNA vaccine expressing HIV-1 gp120 glycoprotein by codon optimization and C3d fusion in a mouse model.
Liu F; Mboudjeka I; Shen S; Chou TH; Wang S; Ross TM; Lu S
Vaccine; 2004 Apr; 22(13-14):1764-72. PubMed ID: 15068860
[TBL] [Abstract][Full Text] [Related]
37. A canarypox vaccine expressing multiple human immunodeficiency virus type 1 genes given alone or with rgp120 elicits broad and durable CD8+ cytotoxic T lymphocyte responses in seronegative volunteers.
Evans TG; Keefer MC; Weinhold KJ; Wolff M; Montefiori D; Gorse GJ; Graham BS; McElrath MJ; Clements-Mann ML; Mulligan MJ; Fast P; Walker MC; Excler JL; Duliege AM; Tartaglia J
J Infect Dis; 1999 Aug; 180(2):290-8. PubMed ID: 10395842
[TBL] [Abstract][Full Text] [Related]
38. HIV gp120-specific cell-mediated immune responses in mice after oral immunization with recombinant Salmonella.
Berggren RE; Wunderlich A; Ziegler E; Schleicher M; Duke RC; Looney D; Fang FC
J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Dec; 10(5):489-95. PubMed ID: 8548327
[TBL] [Abstract][Full Text] [Related]
39. Human immunodeficiency virus type 1 gag-specific mucosal immunity after oral immunization with papillomavirus pseudoviruses encoding gag.
Zhang H; Fayad R; Wang X; Quinn D; Qiao L
J Virol; 2004 Oct; 78(19):10249-57. PubMed ID: 15367590
[TBL] [Abstract][Full Text] [Related]
40. Induction of human immunodeficiency virus type 1 (HIV-1)-specific cytolytic T lymphocyte responses in seronegative adults by a nonreplicating, host-range-restricted canarypox vector (ALVAC) carrying the HIV-1MN env gene.
Egan MA; Pavlat WA; Tartaglia J; Paoletti E; Weinhold KJ; Clements ML; Siliciano RF
J Infect Dis; 1995 Jun; 171(6):1623-7. PubMed ID: 7769304
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
